VERAXA Biotech Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.

VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates. To view the full press release, visit https://ibn.fm/GLFg2.

This partnership underscores a growing trend in the biopharmaceutical industry: leveraging AI to accelerate drug discovery and reduce the high failure rates associated with oncology trials. By using machine learning to parse complex biological data, VERAXA hopes to identify optimal target pairs for its bispecific T-cell engagers (BiTACs), which are designed to engage immune cells more precisely against tumors. The approach could potentially spare patients from the severe side effects often seen with conventional therapies.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.

Forward-looking statements in this article involve risks and uncertainties. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.